4-Hydroxy-7-methoxy-6-nitroquinazoline
- CAS Number:1012057-47-4
- Molecular Formula:C9H7N3O4
- Molecular Weight:221.172
- Mol File:1012057-47-4.mol
Synonyms:4-HYDROXY-7-METHOXY-6-NITROQUINAZOLINE;7-Methoxy-6-nitroquinazolin-4(3H)-one
Physicochemical Properties
- Melting Point:N/A
- Boiling Point:443.8±55.0 °C(Predicted)
- Density:1.60±0.1 g/cm3(Predicted)
- Solubility:N/A
- Flash Point:N/A
- Vapor Density:N/A
- Refractive Index:N/A
- Sensitive:N/A
- Storage Temp.:N/A
- Appearance/Colour:N/A
4-Hydroxy-7-methoxy-6-nitroquinazoline Safety information and MSDS
·Hazard identification:
| Pictogram(s) | no data available |
|---|---|
| Signal word | no data available |
| Hazard statement(s) | no data available |
| Precautionary statement(s) | |
| Prevention | no data available |
| Response | no data available |
| Storage | no data available |
| Disposal | no data available |
·Composition/information on ingredients:
| Chemical name | Common names and synonyms | CAS number | EC number | Concentration |
|---|---|---|---|---|
| 7-methoxy-6-nitro-1H-quinazolin-4-one | 7-methoxy-6-nitro-1H-quinazolin-4-one | 1012057-47-4 | none | 100% |
·First-aid measures:
General adviceConsult a physician. Show this safety data sheet to the doctor in attendance.If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
·Fire-fighting measures:
Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Wear self-contained breathing apparatus for firefighting if necessary.
·Accidental release measures:
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8. Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided. Pick up and arrange disposal. Sweep up and shovel. Keep in suitable, closed containers for disposal.
4-Hydroxy-7-methoxy-6-nitroquinazoline Relevant articles
All total 6 Articles be found
All total 6 Articles be foundTARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
-
Page/Page column 74, (2009/04/24)
The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.
Phenyl [...] compound and its preparation method, pharmaceutical composition, drug use (by machine translation)
-
Paragraph 0272; 0273; 0278; 0279, (2016/10/27)
The invention provides a phenylurea coupling quinazoline compound or a pharmaceutically acceptable salt thereof represented by formula (I), wherein R1 represents H, represents Br, Cl or F, represents -CH3, -CH2-CH3, -CH2(CH3)2 or -CF3, represents -O-CH3, -O-CH2-CH3 or -O-CH2(CH3)2, or represents -C[triple bond]CH or -C[triple bond]N; n1 is 1, 2, 3, 4 or 5; one of R2 and R3 is a group represented by formula (II); R4 represents H, represents Br, Cl or F, represents -CH3, -CH2-CH3, -CH2(CH3)2 or -CF3, represents -O-CH3, -O-CH2-CH3 or -O-CH2(CH3)2, represents -NH2, or represents -NO2; n2 is 1, 2, 3, 4 or 5; and the other one of R2 and R3 represents H, -O-CH3, -O-CH2-CH3, -O-CH2(CH3)2, or the following groups.
MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS
-
Page/Page column 129-130, (2008/06/13)
The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.
FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
-
Page/Page column 73, (2009/05/29)
The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer
Cai, Xiong,Zhai, Hai-Xiao,Wang, Jing,Forrester, Jeffrey,Qu, Hui,Yin, Ling,Lai, Cheng-Jung,Bao, Rudi,Qian, Changgeng
supporting information; experimental part, p. 2000 - 2009 (2010/07/17)
By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clinical development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, respectively. In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. These results suggest that a single compound that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.
4-Hydroxy-7-methoxy-6-nitroquinazoline Synthetic route And Reaction conditions
- 53449-14-2
7-chloro-6-nitro-4(3H)-quinazolinone
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
| Conditions | Yield |
|---|---|
| 77% |
- 124-41-4
sodium methylate
- 53449-14-2
7-chloro-6-nitro-4(3H)-quinazolinone
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
| Conditions | Yield |
|---|---|
| 87.6% |
- 67-56-1
methanol
- 53449-14-2
7-chloro-6-nitro-4(3H)-quinazolinone
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
| Conditions | Yield |
|---|---|
Withsodium;
at 100 ℃;
for 18h; | 97% |
Withsodium;
at 100 ℃;
for 20h; | 77% |
Withsodium;
at 100 ℃;
for 20h; | 77% |
Withsodium;
at 100 ℃;
for 20h; | 77% |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
- 171745-10-1
N-(3-bromophenyl)-7-methoxy-6-nitroquinazoline-4-amine
| Conditions | Yield |
|---|---|
Multi-step reaction with 2 steps 1: 93 percent / POCl3 / 0.5 h / Heating 2: conc. HCl / propan-2-ol / Heating |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
| Conditions | Yield |
|---|---|
Multi-step reaction with 3 steps 1: 93 percent / POCl3 / 0.5 h / Heating 2: conc. HCl / propan-2-ol / Heating 3: Fe / H2O; ethanol |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
- 55496-69-0
4-chloro-7-methoxy-6-nitroquinazoline
| Conditions | Yield |
|---|---|
| 99% | |
Withtrichlorophosphate;
for 0.5h;
Heating; | 93% |
| 85% | |
Withtrichlorophosphate;
for 4h;
Heating / reflux; | 83% |
Withtrichlorophosphate;
for 4h;
Heating / reflux; | 83% |
Withtrichlorophosphate;
for 4h;
Reflux; | 83% |
| 83% | |
Reflux; | |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
- 1012054-73-7
N1-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-N5-hydroxyglutaramide
| Conditions | Yield |
|---|---|
Multi-step reaction with 5 steps 1: trichlorophosphate / 4 h / Heating / reflux 2: isopropyl alcohol / 3 h / Heating / reflux 3: hydrogenchloride; water; iron / ethanol / 1 h / Heating / reflux 4: triethylamine / dichloromethane / 1.33 h / 0 - 20 °C 5: hydroxylamine / methanol / 0.17 h / 0 - 20 °C |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
- 1012057-48-5
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine hydrochloride
| Conditions | Yield |
|---|---|
Multi-step reaction with 2 steps 1: trichlorophosphate / 4 h / Heating / reflux 2: isopropyl alcohol / 3 h / Heating / reflux |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4(3H)-one
- 1146957-64-3
Methyl 3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ylcarbamoyl)propanoate
| Conditions | Yield |
|---|---|
Multi-step reaction with 4 steps 1: trichlorophosphate / 4 h / Heating / reflux 2: isopropyl alcohol / 3 h / Heating / reflux 3: hydrogenchloride; water; iron / ethanol / 1 h / Heating / reflux 4: triethylamine / dichloromethane / 1.33 h / 0 - 20 °C |
- 1012057-47-4
7-methoxy-6-nitroquinazolin-4-ol
| Conditions | Yield |
|---|---|
Multi-step reaction with 4 steps 1.1: 18-crown-6 ether; lithium chloride / N,N-dimethyl-formamide / 4 h / 190 °C 2.1: sodium carbonate / N,N-dimethyl-formamide / 20 °C 2.2: 1 h / 90 °C 3.1: thionyl chloride; N,N-dimethyl-formamide / 5 h / 80 °C 4.1: tetrahydrofuran / 1 h / 20 °C |
4-Hydroxy-7-methoxy-6-nitroquinazoline Raw materials
4-Hydroxy-7-methoxy-6-nitroquinazoline Target Products
- 55496-69-0
4-chloro-7-methoxy-6-nitroquinazoline
- 171745-10-1
N-(3-bromophenyl)-7-methoxy-6-nitroquinazoline-4-amine
- 1353644-75-3
N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxy-6-nitroquinazolin-4-amine
- 897025-61-5
N4-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxyquinazoline-4,6-diamine
- 1353644-76-4
C30H23FN6O3
Business Type:
- Lab/Research institutionsTrading CompanyManufacturers
Certificate:
- Product LicenseEnterprise AuthenticationISOGMPFDAHALAL
Country :
China (Mainland)(15)
United States(1)
Recommended products
- 3-acetyl-N,N-dimethylbenzamide
- (S)-1-(3-methylphenyl)ethane-1,2-diol
- 2-carboxyphenyl-boronic acid sodium salt
- 4-bromo-2-(pyrrolidin-1-yl)benzaldehyde
- 2-aminophenyl N,N-diethylcarbamate
- (R)-1-phenylethyl (5-(4-bromophenyl)-3-methylisoxazol-4-yl)carbamate
- N-<(S)-1-benzyl-2-hydroxy-2-methylpropyl>-2,2,2-trichloroethanamide
- 2-(4-bromobutyl]anisole
- 7-phenyl-1-trimethylsilyl-(5-dibromomethylidene)-1,3,6,-heptatriyne
- 1,3-diphenyl-3-piperidin-1-yl-propan-1-one
- (R)-2-bromo-3-methyl-N-phenylbutyramide
- [4-(3-bromo-propoxy)-phenoxy]-acetic acid methyl ester
- (R)-1-((2-(2,4-difluorophenyl)-4-methylenetetrahydrofuran-2-yl)methyl)-1H-1,2,4-triazole
- bis(ethylthio)diphenylmethane
- 1-benzylcyclopropanemethanol
- Total:16 Page 1 of 1 1
Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields
